(May 10, 2007—ORLANDO, FL)—New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9–12, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease. The Endeavor III trial randomly assigned 436 patients treated at 30 medical centers in the United States to treatment with the investigational Endeavor stent (Medtronic, Minneapolis) or the Cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL). The Endeavor stent is coated with zotarolimus, a medication that, like the Cypher’s sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent. >>> Discuss This Story
